Our Partnering Strategy
Agios is committed to building the leading portfolio of treatments based on insights into cellularmetabolism and precision medicine – fields in which we believe we are poised to delivermultiple novel treatments with the potential to change patients’ lives.
Agios is actively seeking potential collaboration or licensing opportunities that would complement our existing portfolio.
If you are interested in partnering with Agios, please contact us at email@example.com.
In May 2016, Agios and Celgene, a leading biotechnology company, created a new global strategic collaboration focused on metabolic immuno-oncology, an emerging field of cancer research focused on altering the metabolic state of immune cells to enhance the body’s immune response to cancer. The goal of the collaboration is to discover, develop and commercialize novel immuno-oncology therapies based on Agios’ innovative cellular metabolism research platform.
- Agios received an upfront cash payment of $200 million for the initial four-year research term. Celgene has the option to extend the research term for up to two years for a pre-specified amount.
- Exploratory research, drug discovery and early development will be led by Agios.
- Generally, collaboration programs may be designated by Celgene when preclinical studies begin, and Celgene will then have an option on each program up through Phase 1 dose escalation for at least a $30 million fee.
- For metabolic immuno-oncology programs, Celgene and Agios will enter into a global co-development and co-commercialization agreement with a worldwide 50/50 cost and profit share. Agios is eligible for up to $169 million in clinical and regulatory milestone payments for each program.
- The two cancer metabolism programs from the 2010 Agreement, including a program focused on MTAP deleted cancers, are eligible for the same global co-development, co-commercialization and milestone structure described above.
- Celgene will have a one-time opportunity to select a metabolic immuno-oncology program for which costs and profits will be shared 65 percent by Celgene and 35 percent by Agios. Agios may also receive up to $209 million in clinical and regulatory milestone payments for this program.
- For any inflammation or autoimmune programs that may result from the collaboration, Celgene has the option to enter into an exclusive worldwide license agreement and lead worldwide development and commercialization. For any such licensed products, Agios may receive up to $386 million in clinical, regulatory and commercial milestone payments, as well as double-digit tiered royalties on any net sales.
- Agios and Celgene will alternate leadership of all 50/50 programs in the U.S. territory, with Agios making the first program selection.
- Celgene will lead ex-U.S. development and commercialization for all programs. Celgene will lead worldwide development and commercialization for the 65/35 program.
In April 2010, Agios entered into a global strategic collaboration focused on cancer metabolism with Celgene Corporation. The collaboration included a discovery phase, which was completed in April 2016. IDHIFA® (enasidenib) is the first development candidate arising under this agreement. Two additional cancer metabolism programs from the 2010 Agreement, including a program focused on MTAP deleted cancers, were also moved under the new 2016 agreement and are eligible for the same global co-development, co-commercialization and milestone structure as metabolic immuno-oncology programs outlined above.
In April 2015, Agios also entered into a joint worldwide development and profit share collaboration and license agreement with Celgene, focused on the development and commercialization of AG-881. For AG-881, the companies have a joint worldwide development and 50/50 profit share collaboration, and Agios is eligible to receive regulatory milestone payments of up to $70 million.
In October 2016, Agios announced collaboration agreements with Abbott, a leader in diagnostic technologies, to develop and commercialize companion diagnostic tests on Abbott’s m2000 RealTime System to identify isocitrate dehydrogenase (IDH) mutations in acute myeloid leukemia (AML) patients. Celgene is currently developing enasidenib (AG-221/CC-90007), an IDH2 mutant inhibitor, for the treatment of patients with relapsed or refractory AML who have an IDH2 mutation. Agios is developing Ivosidenib, an IDH1 mutant inhibitor, for the treatment of patients with relapsed or refractory AML who have an IDH1 mutation. Celgene and Agios have entered into separate agreements with Abbott to develop diagnostic tests to identify IDH2 and IDH1 mutations, respectively.
In March 2013, Agios entered into a multi-year diagnostic partnership with Foundation Medicine for Agios’ lead programs in cancer metabolism. These programs focus on developing new cancer metabolism inhibitors targeting tumors carrying mutations in either the IDH1 or IDH2 metabolic enzymes. Foundation Medicine and Agios are collaborating to identify tumor genomic alterations that can be used to identify which patients are most likely to respond to Agios’ IDH1 and IDH2 investigational medicines.